Prenetics Global (NASDAQ:PRE) Rating Lowered to "Sell" at Wall Street Zen

Prenetics Global logo with Consumer Staples background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Prenetics Global from “hold” to “sell.” Analyst views remain mixed, however: MarketBeat reports an overall “Moderate Buy” consensus and a $36.17 average price target.
  • The stock opened at $8.80, near its one-year low of $8.69, and well below its 50-day and 200-day moving averages of about $19. The company reported a quarterly loss of $1.45 per share on $64.11 million in revenue.
  • Company insiders have been buying shares: executives acquired 40,281 shares worth about $862,000 over the past 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Prenetics Global (NASDAQ:PRE - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research firms have also recently commented on PRE. Craig Hallum assumed coverage on shares of Prenetics Global in a research note on Thursday, September 17th. They set a "buy" rating and a $40.00 target price for the company. Lucid Cap Mkts raised shares of Prenetics Global to a "strong-buy" rating in a research note on Monday, October 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Prenetics Global in a report on Thursday, October 15th. B. Riley Financial cut their price objective on Prenetics Global from $37.00 to $31.00 and set a "buy" rating for the company in a research note on Thursday. Finally, Maxim Group began coverage on Prenetics Global in a research note on Monday, October 26th. They set a "buy" rating and a $41.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Prenetics Global presently has an average rating of "Moderate Buy" and a consensus target price of $36.17.

Get Our Latest Research Report on Prenetics Global

Prenetics Global Stock Performance

Prenetics Global stock opened at $8.80 on Friday. The company's fifty day moving average price is $19.24 and its 200 day moving average price is $19.38. Prenetics Global has a 1 year low of $8.69 and a 1 year high of $27.24. The stock has a market capitalization of $148.46 million, a P/E ratio of -1.73 and a beta of 0.40.

Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Sunday, November 1st. The company reported ($1.45) earnings per share for the quarter. The company had revenue of $64.11 million for the quarter. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. Sell-side analysts predict that Prenetics Global will post -2.36 EPS for the current year.

Insider Buying and Selling at Prenetics Global

In other Prenetics Global news, CEO Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock in a transaction dated Monday, August 24th. The stock was acquired at an average cost of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the transaction, the chief executive officer directly owned 112,416 shares of the company's stock, valued at approximately $2,386,591.68. This represents a 18.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Brian J. Rosin bought 5,100 shares of Prenetics Global stock in a transaction dated Tuesday, August 25th. The stock was acquired at an average price of $22.80 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer directly owned 23,100 shares of the company's stock, valued at approximately $526,680. The trade was a 28.33% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 40,281 shares of company stock worth $862,453. 7.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Prenetics Global

Large investors have recently bought and sold shares of the business. State of Wyoming purchased a new position in Prenetics Global in the 1st quarter worth approximately $48,000. Stevens Capital Partners boosted its holdings in shares of Prenetics Global by 9.0% during the 3rd quarter. Stevens Capital Partners now owns 30,674 shares of the company's stock worth $709,000 after purchasing an additional 2,527 shares during the last quarter. Operose Advisors LLC acquired a new position in shares of Prenetics Global during the 2nd quarter worth approximately $129,000. Virtu Financial LLC purchased a new stake in shares of Prenetics Global in the third quarter valued at approximately $252,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Prenetics Global in the third quarter valued at approximately $253,000. Hedge funds and other institutional investors own 25.01% of the company's stock.

About Prenetics Global

(Get Free Report)

Prenetics Global Limited is a health sciences company focused on consumer wellness and health-related products. Its portfolio includes IM8, a consumer wellness brand offering nutritional supplements, and CircleDNA, a genetic testing service that provides reports on health, wellness and ancestry. The company has also operated clinical genomic testing services and provided COVID-19 testing during the pandemic. Its business has since shifted toward consumer health and wellness. Prenetics was founded in 2014 and is led by co-founder and Chief Executive Officer Danny Yeung.

Recommended Stories

Analyst Recommendations for Prenetics Global (NASDAQ:PRE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Prenetics Global Right Now?

Before you consider Prenetics Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.

While Prenetics Global currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines